This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BioDelivery Sciences Announces Hiring Of David Acheson As Vice President Of Sales And Managed Markets

RALEIGH, N.C., Dec. 3, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the hiring of David Acheson as Vice President of Sales and Managed Markets. 

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

David joins BDSI with over 18 years of pharmaceutical and biotech sales and commercial experience.  David will oversee the sales and managed markets support behind the anticipated launch of BUNAVAIL in 2014 as well as both current and future commercial partnerships.

David's most recent relevant experience was leading the strategy and full build out and deployment of the sales organization for Pacira Pharmaceuticals Inc., an emerging specialty pharmaceutical company focused on the clinical and commercial development of products in the post-surgical pain market, where he played an instrumental role in the successful introduction of Exparel in 2012.  Most recently, David was with CSL Behring as the National Director of Sales, Immunology and Pulmonary for two specialty teams focused in rare and orphan diseases. 

"We are extremely fortunate to have someone with David's talent and energy join our management team during this exciting and evolutionary phase of our company as we progress from a research and development focused company to a broader commercial entity," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "The timing of David's hiring is significant as we finalize our commercial plans for BUNAVAIL over the next several months.  In parallel with our partnering discussions, we are making the appropriate plans to also launch BUNAVAIL.  Regardless of which pathway we ultimately determine provides the best opportunity for the long term success of BUNAVAIL and BDSI's other products, David will oversee the sales and managed markets effort."

David's pharmaceutical and biotech career began with Roche Pharmaceuticals where he worked as a Sales Representative, Medical Center Representative and Division Sales Manager.  After five years in the hospital and oncology supportive care arena at Roche, David joined MedPointe/Meda Pharmaceuticals working his way through multiple areas of responsibility in sales as a District Sales Manager, Regional Sales Director and National Sales Director in the respiratory business.  Also at Meda, David served as the National Sales Director, Pain and Supportive Care Team, and was responsible for building a full pain and oncology supportive care division of the company from scratch, deploying a full sales team as well as operational needs within the company.  David has experience in a number of complex markets such as pain, palliative care, immunotherapy and orphan disease state products, many of which afforded him a great deal of involvement in the equally complex managed markets settings, developing and executing payer strategies as well as partnerships at the distribution and channel level.  David has worked in collaborative partnerships and has significant experience working with contract sales organizations.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs